Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension
Spironolactone treatment in patients with diabetic microalbuminuria and resistant hypertension
复制标题
DOI：
10.1007/s13410-012-0063-5
复制
发表时间：
2012-03-01
影响因子：
0.9
通讯作者：
Modi, Kirtikumar D.
中科院分区：
文献类型：
--
作者：
Kota, Sunil Kumar;Jammula, Sruti;Modi, Kirtikumar D.
顽固性高血压在糖尿病中很常见。螺内酯通过抑制醛固酮不仅发挥降压作用，而且还具有抗蛋白尿作用。在这项研究中，螺内酯治疗 4 周后，收缩压和舒张压平均下降分别为 25.5 +/- 7.8 和 11.4 +/- 3.5 mmHg，并在 8 周和 12 周时进一步增加，而对照组血压没有显着变化。第 12 周时，与血清钾高于 4 meq/l 的患者相比，血清钾低于 4 meq/l 的螺内酯治疗患者的收缩压和舒张压显着降低。尽管血清钾低于 4 meq/l 的患者尿微量白蛋白含量较高，但尿微量白蛋白减少，但在任何时间间隔都不显着。
Resistant hypertension is common in diabetes. Spironolactone by inhibiting aldosterone not only exerts antihypertensive effect but also antiproteinuric effect. In this study, the mean decrease in systolic and diastolic blood pressure after 4 weeks of spironolactone was 25.5 +/- 7.8 and 11.4 +/- 3.5 mmHg respectively and it increased further at 8 weeks and at 12 weeks, while there was no significant change in blood pressure in the control group. At 12 weeks, significantly greater reductions in both the systolic and diastolic blood pressure were observed in patients treated with spironolactone having serum potassium less than 4 meq/l vs those having serum potassium more than 4 meq/l. Reduction in urine microalbumin, though higher in patients with serum potassium less than 4 meq/l was not significant at any intervals.